KEYNOTE-A17: First-Line Pembrolizumab Plus Cisplatin-Pemetrexed in Japanese Participants With Advanced Pleural Mesothelioma. Kijima T, Kato T, Goto Y, Kuribayashi K, et al. Cancer Sci 2025;116:2208-2217.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Kijima T, Kato T, Goto Y, Kuribayashi K, et al. KEYNOTE-A17: First-Line Pembrolizumab Plus Cisplatin-Pemetrexed in Japanese Participants With Advanced Pleural Mesothelioma. Cancer Sci 2025;116:2208-2217.
PMID: 40407381